Navigation Links
New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation
Date:2/11/2009

on the primary composite endpoint of all-cause mortality combined with cardiovascular hospitalization compared with placebo. The pre-specified secondary endpoints were death from any cause, cardiovascular death and hospitalization for cardiovascular reasons. The pre-specified safety endpoint was the incidence of treatment emergent adverse events (between first study drug intake and last study drug intake plus 10 days) including all adverse events, serious adverse events and adverse events leading to study drug discontinuation.

About Atrial Fibrillation

AF is a common heart arrhythmia in which the upper chambers of the heart beat in an uncoordinated and disorganized fashion, which can cause palpitations, shortness of breath and fatigue. AF currently represents a major economic burden for society. Seventy percent of the annual cost of AF management in Europe is driven by in-patient care and interventional procedures. Hospitalizations for AF have increased dramatically (two-to-three-fold) in recent years. AF hospitalizations now represent a third of all hospitalizations for arrhythmia and mortality in the US and Europe. AF affects nearly 7 million people in the European Union and the United States.

The condition is increasingly frequent with advancing age and is often caused by age-related changes in the heart or as a result of cardiovascular disease. AF increases the risk of stroke up to five-fold and heart failure two-to-three-fold. AF also doubles the risk of mortality.

Without appropriate management, AF can lead to serious complications such as stroke and congestive heart failure. In addition to preventing stroke and reducing the burden of the disease, successful management of AF should also aim at further reducing cardiovascular morbidity and mortality.

The goals of treatment for patients with AF are related to managing the arrhythmia itself and to the prevention of t
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
2. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
3. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
4. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
5. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
6. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
7. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
8. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
9. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
10. New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
11. Diamyd(R) Study Published in Prestigious New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 Today, ... that modify the religious "accommodation" but still require ... that have an abortifacient effect, including Plan B ... after pill"). The Obama Administration also announced that ... closely held, for-profit corporations. The regulations ...
(Date:8/22/2014)... Aug. 22, 2014  Dr. Mark Rasak , ... Diamond Lifetime Achievement Award in the field of Medicine ... Cardiovascular Clinical Associates. Dr. Rasak has over ... major aspects of the business; overseeing the daily operations; ... coronary intervention. In addition, he is an honored Fellow ...
(Date:8/22/2014)... Cali ., Aug. 22, 2014  Research ... shows that a therapy being developed by Hera Therapeutics Inc. ... cause 70 percent of all cervical cancer. When ... replication of HPV-16, HPV-18 and HPV-11 cells, according to ... Ph.D., who presented the findings at the Seattle ...
Breaking Medicine Technology:Liberty Institute: Government "Accommodation" Still Requires Employers To Facilitate Coverage Of Abortifacient Drugs 2Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
... At its regularly scheduled meeting on September 14, ... (the "Company" or "AMPAC") (Nasdaq: APFC ) ... that shareholders at the next Annual Meeting amend AMPAC,s ... for director election with a simple majority vote requirement. ...
... U.S. Food and Drug Administration (FDA), working in close ... announced that Forest Pharmaceuticals, Inc. entered into a plea ... actions including distribution of an unapproved new drug, distribution ... inspection. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ...
Cached Medicine Technology:American Pacific Adopts Corporate Governance Changes 2Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws 2Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws 3
(Date:8/23/2014)... 23, 2014 Legal Insider Bot ... by Greg Marks has been generating a buzz of ... The commotion surrounding the new product has drawn the ... , “In recent years the market has ... commonly referred to as robots or ‘bots,'” reports Hendricks. ...
(Date:8/23/2014)... GBI Research, the leading business intelligence ... in Major Developed Markets to 2020 - New and ... which provides in-depth analysis of the critical care market ... and Canada. The report provides an estimation of market ... It covers critical care indications that are being treated ...
(Date:8/23/2014)... August 23, 2014 Professional kitchen employees, ... study aid in preparing for Food Safety Certification exams ... by Dynamic Path. , Dynamic Path announced the ... includes more than 200 review questions for culinary industry ... designed to cover requirements of the ServSafe® Food Safety ...
(Date:8/23/2014)... (PRWEB) August 23, 2014 Young adults in Athens, ... doing drugs should pick up the phone and call the new ... teen drug addict . , Troubled Teen Athens is a ... ready to finally take the necessary steps to end substance abuse ... are quick to go to friends or peers when really they ...
(Date:8/23/2014)... 23, 2014 Youth substance abuse is ... no different in Houston, TX. Substance abuse can happen ... to drug and alcohol dependency in higher numbers than ... beat substance abuse, but don’t know where to find ... can be a challenge because most treatment options are ...
Breaking Medicine News(10 mins):Health News:Legal Insider Bot Review Examining Greg Marks’ Trading Software Released 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 3Health News:Food Handler Safety Certification Made Easy with Dynamic Path 2Health News:Teenagers in Athens, GA are Locating Addiction Recovery Thanks to New Helpline 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2
... of the population but account for nearly 20 percent ... major risk factor for // suicide in the elderly. ... thoughts in depressed elderly patients. ,Researchers from ... 600 elderly patients with depression. Some patients were assigned ...
... skin’s worst enemies, but now some dermatologists are taking cues from sunlight ... phototherapy. ,Standing in front of a UV light is ... from a disease called morphea , it can affect any area of ... joints, also known as localized scleroderma. She says: “I had a bunch ...
... can be a significant predictor of breast cancer risk for ... ,In 1992, researchers sampled nearly 62,000 women, ages ... age 18 and their current weight. Since then, the women ... in addition to any diagnosis of cancer. Research shows ...
... Around 165,000 cases of lung cancer are diagnosed in ... to 25 percent are classified // as small cell ... and the disease frequently travels to the brain and ... cancer, for example, ranges up to 80 percent. Whether ...
... a new drug is showing promising results.For the past ... recombinant immunotoxins. An immunotoxin is bioengineered and consists of ... antibodies that are commonly used to fight leukemia. One ... a phase II study. ,Researchers say in a ...
... A recent study has shown that a chemotherapy regimen ... prednisone is effective in the treatment of hormone-refractory prostate ... to symptomatic patients earlier in their disease. ... study of this treatment regimen is planned. From a ...
Cached Medicine News:Health News:A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer 2
Sterile cordless eraser tips, packsize is 10/box....
Hydroview insertion forcep with very thin jaws to allow insertion through tunnel or clear cornea incision. Locking. Made in titanium....
Bi-angled insertion jaws designed to enhance surgeon comfort and efficiency. Reverse action releases lens when handle is compressed. Made in titanium....
45 degree. Angled shafts. Tip to angle length: 11.5 mm. Stops in handle designed to prevent "over folding". Manufactured in titanium....
Medicine Products: